HLOSF (Healios KK) Operating Margin %: -14,242.00% (As of Mar. 2026)


HLOSF Healios KK HLOSF
57 GF Score
Price $1.80
GF Value $0.42
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Operating Margin %?

Healios KK HLOSF 57 Operating Margin % is -14,242.00% as of Mar. 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 942 Biotechnology companies, Healios KK ranks worse than 89.38% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Healios KK's Operating Income for the three months ended in Mar. 2026 was $-7.12 Mil. Healios KK's Revenue for the three months ended in Mar. 2026 was $0.05 Mil. Therefore, Healios KK's Operating Margin % for the quarter that ended in Mar. 2026 was -14,242.00%.

Good Sign:

Healios KK operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Healios KK's Operating Margin % or its related term are showing as below:

HLOSF' s Operating Margin % Range Over the Past 10 Years
Min: -15496.3   Med: -4826.97   Max: -507.5
Current: -5035.14


HLOSF's Operating Margin % is ranked worse than
89.38% of 942 companies
in the Biotechnology industry
Industry Median: -86.83 vs HLOSF: -5035.14

Healios KK's 5-Year Average Operating Margin % Growth Rate was 40.80% per year.

Healios KK's Operating Income for the three months ended in Mar. 2026 was $-7.12 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-24.46 Mil.


Healios KK  (OTCPK:HLOSF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Healios KK Operating Margin % Related Terms


Healios KK Operating Margin % Historical Data

* Premium members only.

The historical data trend for Healios KK's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healios KK Operating Margin % Chart

Healios KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,138.06 -5,755.17 -2,793.81 -507.47 -3,211.69

Healios KK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,957.25 -3,779.61 -4,010.16 -4,036.88 -14,242.00

HLOSF vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Healios KK's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healios KK Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Healios KK's Operating Margin % falls into.


HLOSF
57GF Score
Healios KK HLOSF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healios KK Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Healios KK's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-21.422 / 0.667
=-3,211.69 %

Healios KK's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-7.121 / 0.05
=-14,242.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -14,242.00% mean?
Healios KK (HLOSF) has a Operating Margin % of -14,242.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #842 out of 942 companies in the Biotechnology industry, placing it in the top 89.4%.
Is Healios KK's Operating Margin % too high?
Healios KK's current Operating Margin % is -14,242.00%. Based on the distribution chart, Healios KK ranks #842 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #842 out of 942 companies for Operating Margin %. This places Healios KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Healios KK and its competitors. Healios KK's current Operating Margin % is -14,242.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $1.80 — trading 328.6% above its estimated fair value. The current Operating Margin % is -14,242.00%. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Healios KK (HLOSF), the current Operating Margin % is -14,242.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (HLOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of $1.80 is trading 328.6% above its estimated GF Value™ of $0.42. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for HLOSF:

  • Operating Margin %: -14,242.00%
  • GF Value™: $0.42 vs. price of $1.80 (328.6% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healios KK Business Description

Other Exchanges 4593:Japan6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score

Get the complete analysis for HLOSF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.42
GF Value